头孢哌酮-舒巴坦联合阿奇霉素治疗社区获得性肺炎的临床观察

Clinical Investigation on Cefoperazone/Sulbactam and Azithromycin in the Treatment of Community-Acquired Pneumonia

目的观察头孢哌酮-舒巴坦联合阿奇霉素治疗社区获得性肺炎(community-acquired pneumonia,CAP)的临床疗效和不良反应。方法将48例CAP患者,随机分为两组,治疗组为头孢哌酮-舒巴坦联合阿奇霉素组(n=24),对照组为单纯用头孢哌酮-舒巴坦(n=24),疗程均为7～14d,观察两组患者的临床疗效和不良反应。结果治疗组总有效率为95.83%,对照组的总有效率为83.33%,两组的临床疗效比较差异有统计学意义(P<0.05)。治疗组不良反应发生率12.50%,对照组不良反应发生率8.33%,两组不良反应发生率比较差异无统计学意义(P>0.05)。结论头孢哌酮-舒巴坦联合阿奇霉素治疗CAP可提高疗效,缩短病程,且耐受性良好。

Objective To evaluate the efficacy and safety of cefoperazone/sulbactam and azithromycin in the treatment of community-acquired pneumonia（CAP）.Methods 48 patients with CAP were randomly divided into two groups：treatment group：the patients were treated with cefoperazone/sulbactam and azithromycin,control group：the patients were treated with cefoperazone/sulbactam alone.Both groups were treated for 7～14 days.Efficacy and safety of cefoperazone/sulbactam and azithromycin in the treatment were observed.Results The overall efficacy was 95.83% for the treatment group and 83.33% for control group.The results showed that there were significant differences between the two groups（P〈0.05）;The rates of the side effects were 12.50% and 8.33%,respectively.There were no significant differences between the two groups（P〈0.05）.Conclusion Cefoperazone/sulbactam and azithromycin in the treatment of community-acquired pneumonia（CAP） can improve efficacy,shorten the course of disease and are well tolerated.